Citations

Clear

7552 citation(s) found for "Ho, Matthew".

The association of early toxicity and outcomes for patients treated with abemaciclib.
Forrester, Tammy , Frenzel, Martin, Cox, Joanne, Barriga, Susana , Tolaney, Sara M. , Rugo, Hope S. , Sledge, George W. , Johnston, Stephen , Goetz, Matthew P. , Martín, Miguel , Toi, Masakazu

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1053-1053

10.1200/jco.2018.36.15_suppl.1053 Get It

Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.
Neven, Patrick , Tolaney, Sara M. , Barriga, Susana , Rugo, Hope S. , Iwata, Hiroji , Toi, Masakazu , Goetz, Matthew P. , Kaufman, Peter A. , Lin, Yong , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1002-1002

10.1200/jco.2018.36.15_suppl.1002 Get It

Clinical performance pilot using cognitive computing for clinical trial matching at Mayo Clinic.
Helgeson, J. , Rammage, Melissa, Urman, Alexandra, Roebuck, M. Christopher , Coverdill, Sadie, Pomerleau, K. , Liu, Li‐Ing, Sweetman, Robert, Chau, Quincy, Vinegra, Michael , Haddad, Tufia C. , Dankwa‐Mullan, Irene , Williamson, M Paul, Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e18598-e18598

10.1200/jco.2018.36.15_suppl.e18598 Get It

Impact of a cognitive computing clinical trial matching system in an ambulatory oncology practice.
Haddad, Tufia C. , Helgeson, J. , Pomerleau, K. , Makey, Marissa, Lombardo, Phillip, Coverdill, Sadie, Urman, Alexandra, Rammage, Melissa, LaRusso, Nicholas, Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6550-6550

10.1200/jco.2018.36.15_suppl.6550 Get It

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
Arriaga, Yull , Milowsky, Matthew I. , Currie, Graeme, Abella, Steve, Pal, Sumanta K. , Bellmunt, Joaquim , Picus, Joel , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4534-4534

10.1200/jco.2018.36.15_suppl.4534 Get It

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Hu, James , Srinivas, Sandy, Costello, Brian A. , Milowsky, Matthew I. , Bromberg, Maria , Nolan, Patrick , Dorff, Tanya B. , Reuter, Victor E. , Bajorin, Dean F. , Feldman, Darren Richard , Stadler, Walter M. , Appleman, Leonard J. , Patil, Sujata N , Al-Ahmadie, Hikmat A , Funt, Samuel A. , Bosl, George J. , Quinn, David I , Motzer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4508-4508

10.1200/jco.2018.36.15_suppl.4508 Get It

Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Hobday, Timothy J. , Hendifar, Andrew , Ravasi, Laura, Öberg, Kjell E., Ruszniewski, Philippe, Krenning, Eric P. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4102-4102

10.1200/jco.2018.36.15_suppl.4102 Get It

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Hobday, Timothy J. , Hendifar, Andrew , Sierra, Maribel Lopera , Öberg, Kjell E., Ruszniewski, Philippe, Krenning, Eric P. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4099-4099

10.1200/jco.2018.36.15_suppl.4099 Get It

Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.
Tolaney, Sara M. , Campone, Mario , Barriga, Susana , Leo, Angelo Di , Llombart‐Cussac, Antonio , Dickler, Maura N. , Iwata, Hiroji , Toi, Masakazu , Kaufman, Peter A. , André, Valérie , Goetz, Matthew P. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1048-1048

10.1200/jco.2018.36.15_suppl.1048 Get It